Anemia Treatments

Find Anemia Treatments

Generic Name

Epoetin

Brand Names

Epogen, Procrit, Retacrit

FDA approval date: June 01, 1989

Classification: Erythropoiesis-stimulating Agent

Form: Injection, Solution

What is Epogen (Epoetin)?

Epogen is an erythropoiesis-stimulating agent indicated for: Treatment of anemia due to: - Chronic Kidney Disease in patients on dialysis and not on dialysis.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Procedure, Drug, Biological, Other, Radiation

Study Phase: Phase 2

Summary: This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A b...

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Enrollment Status: Recruiting

Publish Date: June 15, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alf...

A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Enrollment Status: Recruiting

Publish Date: May 22, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis

View All Clinical Trials